trending Market Intelligence /marketintelligence/en/news-insights/trending/a8o-ervm7i2mxn7qt6lvfg2 content esgSubNav
In This List

Helix, ProMab to develop cell-based treatment for multiple myeloma


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Helix, ProMab to develop cell-based treatment for multiple myeloma

Helix BioPharma Corp. has completed an agreement with ProMab Biotechnologies, Inc. to develop a cell-based therapy to prevent and treat solid tumors.

The Richmond, Ontario-based company will collaborate with ProMab to develop chimeric antigen receptor T cell, or CAR-T, technologies for certain hematological malignancies.

The identified treatment will be developed for multiple myeloma, a type of blood cancer. Helix retains the commercial rights to the CAR-T cell therapy in Canada and Europe.

SNL Image

The program intends to start human trials by early 2019.

Helix said it continues to prioritize its DOS47 drug development, particularly its clinical L-DOS47 and V-DOS47 preclinical programs, both for treating cancers.